» Articles » PMID: 36175642

Influenza A Virus Neuraminidase Inhibitors

Overview
Specialty Molecular Biology
Date 2022 Sep 29
PMID 36175642
Authors
Affiliations
Soon will be listed here.
Abstract

Depending on the strain, influenza A virus causes animal, zoonotic, pandemic, or seasonal influenza with varying degrees of severity. Two surface glycoprotein spikes, hemagglutinin (HA) and neuraminidase (NA), are the most important influenza A virus antigens. NA plays an important role in the propagation of influenza virus by removing terminal sialic acid from sialyl decoy receptors and thereby facilitating the release of viruses from traps such as in mucus and on infected cells. Some NA inhibitors have become widely used drugs for treatment of influenza. However, attempts to develop effective and safe NA inhibitors that can be used for treatment of anti-NA drugs-resistant influenza viruses have continued. In this chapter, we describe the following updates on influenza A NA inhibitor development: (i) N-acetylneuraminic acid (Neu5Ac)-based derivatives, (ii) covalent NA inhibitors, (iii) sulfo-sialic acid analogs, (iv) N-acetyl-6-sulfo-β-D-glucosaminide-based inhibitors, (v) inhibitors targeting the 150-loop of group 1 NAs, (vi) conjugation inhibitors, (vii) acylhydrazone derivatives, (viii) monoclonal antibodies, (ix) PVP-I, and (x) natural products. Finally, we provide future perspectives on the next-generation anti-NA drugs.

Citing Articles

TRIM46 accelerates H1N1 influenza virus-induced ferroptosis and inflammatory response by regulating SLC7A11 ubiquitination.

Zhou C, Bao G, Chen Y J Bioenerg Biomembr. 2024; 56(6):631-643.

PMID: 39531094 DOI: 10.1007/s10863-024-10043-w.


A Systematic Review of Clinical Pharmacokinetics of Inhaled Antiviral.

Alshammari M, Almutairi M, Althobaiti M, Alsawyan W, Alomair S, Alwattban R Medicina (Kaunas). 2023; 59(4).

PMID: 37109600 PMC: 10145512. DOI: 10.3390/medicina59040642.

References
1.
Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M . New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013; 9(10):e1003657. PMC: 3794996. DOI: 10.1371/journal.ppat.1003657. View

2.
Wang K, Lei Z, Zhao L, Chen B, Yang F, Liu K . Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A. Eur J Med Chem. 2019; 185:111841. DOI: 10.1016/j.ejmech.2019.111841. View

3.
de Vries E, Du W, Guo H, de Haan C . Influenza A Virus Hemagglutinin-Neuraminidase-Receptor Balance: Preserving Virus Motility. Trends Microbiol. 2019; 28(1):57-67. PMC: 7172302. DOI: 10.1016/j.tim.2019.08.010. View

4.
Kiefel M, von Itzstein M . Influenza virus sialidase: a target for drug discovery. Prog Med Chem. 2000; 36:1-28. DOI: 10.1016/s0079-6468(08)70044-4. View

5.
Kim C, Lew W, Williams M, Liu H, Zhang L, Swaminathan S . Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997; 119(4):681-90. DOI: 10.1021/ja963036t. View